Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance
Twice-daily dosing of Dolutegravir is approved for adults with HIV and integrase strand transfer inhibitor resistance, but not for children. Population pharmacokinetic modeling and simulations identified a weight-tiered twice-daily dose for children, predicted to yield dolutegravir exposures within the therapeutic window and provide similar efficacy and safety as seen in adults with HIV-1 and first-generation integrase strand transfer inhibitor resistance.
Authors
- Rashmi Mehta (ORCID: https://orcid.org/0000-0002-6824-9473)
- Theodore Ruel (ORCID: https://orcid.org/0000-0002-1105-9126)
- Hardik Chandasana (ORCID: https://orcid.org/0000-0002-1289-0800)
- Michael J. McKenna (ORCID: https://orcid.org/0000-0001-9998-0093)
- M. Bush (ORCID: https://orcid.org/0000-0002-0040-7957)
- Lionel Tan (ORCID: https://orcid.org/0000-0002-3822-497X)
- Cindy Brothers
- Ana Cristina Puga
- Cassidy Henegar
- Cindy Vavro
- Linda Lewis
Institutions
- University of California, San Francisco (US)
- Baylor College of Medicine (US)
- ViiV Healthcare (Spain) (ES)
- Clinton Health Access Initiative (US)
- ViiV Healthcare (United Kingdom) (GB)
- Simulation Technologies (United States) (US)
- System Simulation (United Kingdom) (GB)
- Health and Safety Executive (GB)
Publication Details
- Journal
- The Pediatric Infectious Disease Journal
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1097/inf.0000000000005158
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00